Objectives: The emergence of oseltamivir-resistant viruses raised the global threat with regard to influenza virus infection. To develop alternative antiviral agents against influenza virus infection is significant and urgent.
Introduction
Influenza is a highly contagious, acute, febrile, respiratory illness. The native hosts of influenza virus are wild water fowl and ducks; however, the virus can infect various host species, including humans, whales, swine, horses, cattle, chickens and even cats and tigers. 1 Influenza virus is an enveloped RNA virus, belonging to the family Orthomyxoviridae. 2 Its viral characteristics include a segmented genome structure that is attributed to the mechanism of reassortment and an RNA polymerase complex that contributes to a higher mutation rate; influenza virus has a very diverse genomic background. Because of this genomic diversity and the wide variety of its hosts, influenza virus causes not only annual epidemics but also occasional pandemics. The 1918 influenza pandemic killed 50 million people in 1 year. 3 The other two pandemics caused by the H2N2 and H3N2 subtypes of influenza A viruses in 1957 and 1968, respectively, also killed millions of people. 4, 5 In recent years, the continuous outbreaks of the H5N1 subtype of influenza A virus in poultry in many Asian countries have been posing a threat to humans because of the high risk of another pandemic. 6 -10 More recently, a swine-origin influenza A (H1N1) virus that is being spread via human to human transmission has become a serious public concern around the world, highlighting again that influenza virus is a very significant pathogen with the unique characteristic of causing pandemics. 11 -14 Although vaccination is a good strategy for preventing and controlling seasonal influenza virus infections, antigenic drift may cause viruses to escape antibodies in vaccinated humans. Antiviral therapy is an effective means of prevention, control and treatment of influenza virus infection. However, an increasing number of amantadine-or oseltamivir-resistant viruses have emerged. 15 -22 For example, most human influenza A H1N1 (seasonal flu) viruses were found to be resistant to oseltamivir, and many human influenza A H3N2 viruses were resistant to amantadine. 19,21 -26 Hence, the development of more anti-influenza viral agents with various molecular targets is both urgent and important. Numerous efforts are under way to develop new antiviral agents for influenza treatment. 27 For example, DAS181 (Fludase; NexBio), which can be mass-produced in Escherichia coli, is a fusion construct that incorporates the sialidase from Actinomyces viscosus that is linked to human epithelium-anchoring domains. 28 This agent targets the viral attachment process. T705 (Toyama Chemical), another potential anti-influenza virus agent, targets viral RNA polymerase through a nucleoside analogue competition mechanism. 29, 30 While there are several potential antiinfluenza viral agents being developed, the need to find more antivirals remains because combination therapy is a promising strategy for the treatment of RNA viruses, including influenza virus.
In this study we conducted a cell-based screening assay of at least 20 000 compounds and identified several promising compounds that inhibit replication of influenza virus. BPR2-D2 was obtained from one of the active compounds. The inhibition of oseltamivir-resistant viruses was examined and potential molecular targets and the corresponding mechanism were also elucidated.
Materials and methods

Cells, viruses and plasmids
293T cells were grown in complete Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Madin-Darby canine kidney (MDCK) cells were grown in Eagle's minimum essential medium (MEM) supplemented with 10% FBS. Influenza virus A/WSN/33 (H1N1) (WSN) was purchased from ATCC. Trypsin (2.5 mg/mL) was added to MEM for virus amplification, neutralization test and plaque reduction assay for influenza virus.
The four plasmids amplified using pcDNA plasmids encoding the sequences corresponding to the PB2, PB1, PA and NP genomic segments of WSN virus were kindly provided by George G. Brownlee, University of Oxford, UK. Plasmid pPolI-CAT-RT expressing the influenza virus-like RNA driven by a truncated human RNA Pol I promoter was also kindly provided by George G. Brownlee, University of Oxford, UK. 31 It contains the chloramphenicol acetyltransferase (CAT) gene open reading frame in negative orientation, flanked by the 3 0 -and 5 0 -non-coding region of the NS segment of WSN virus.
Neutralization test
Confluent MDCK cells in 96-well tissue culture plates were added to influenza virus. The cells were then mixed with various concentrations of test compounds before incubation was performed at 378C for 1 h. Following adsorption, the infected cell plates were overlaid with 50 mL of DMEM plus 2% DMSO. After they had been incubated at 378C for 48 h, the plates were fixed by adding 100 mL of 0.5% formaldehyde for 1 h at room temperature. Following removal of the formaldehyde, the plates were stained with 0.1% Crystal Violet for 15 min at room temperature. The plates were then washed and dried, and the density of the well was measured at 570 nm by a VERSAmax microplate reader. The concentration required for a test compound to reduce the virus-induced cytopathic effect (CPE) by 50% relative to the virus control was expressed as the 50% effective dose (EC 50 ). All assays were performed three times.
For 5 cells/mL in DMEM with 10% FBS. The plates were further incubated for 24 h at 378C. Virus (100 TCID 50 , 50% tissue culture infective doses) was added to the cells and incubated at 358C for 1 h. Following adsorption, the infected cells were overlaid with 50 mL of DMEM plus 2% FBS and 0.5% DMSO or BPR2-D2. The plates were incubated at 378C for 64 h. At the end of the incubation, the plates were fixed by adding 100 mL of 0.5% formaldehyde for 1 h and then staining with 0.1% Crystal Violet. The well density was determined at 570 nm by a VERSAmax microplate reader. The concentration of BPR2-D2 required to reduce the virus-induced CPE by 50% in relation to the virus control was expressed as the EC 50 . Each experiment was performed in triplicate and repeated at least twice. The neutralization test for HSV-2 was performed in the same manner as that for enteroviruses and rhinovirus except that Vero cells were used.
Cytotoxicity test
Serial dilutions of BPR2-D2 were incubated with MDCK cells. Following incubation for 72 h, cells were fixed with paraformaldehyde and stained with 0.1% Crystal Violet; the optical density (OD) at 570 nm was measured in a microtitre plate reader. The percentage viability is expressed in relation to the vehicle control.
Plaque reduction assay
Different concentrations of compounds in a maintenance medium with trypsin were added to monolayers of MDCK cells in 6-well plates. Virus (250 pfu) was then added to each well that contained 5Â10 5 
cells [multiplicity of infection (MOI)¼5Â10
24 ]. The plates were then incubated for 1 h at 378C for viral adsorption. After that, 3 mL of overlay medium was supplemented with 3% agarose and the compound was added. After they had been incubated for 48 h at 378C, the cells were fixed with 10% formalin for 1 h. After the formalin had been removed, the cells were stained with Crystal Violet and plaques were visualized. Visible plaques were counted, and the number of pfu/mL was determined. The numbers and sizes of plaques were obtained from at least three independent experiments.
Primer extension assay
Primer extension reactions were performed using a primer extension system-the AMV Reverse Transcriptase kit (Promega)-following the manufacturer's instructions. Briefly, 5 mg of total RNA was mixed with CAT vRNA-specific 32 P-labelled primer and positive-sense RNA-specific Shih et al.
P-labelled primer, ATGTTCTTTACGATGCGATTGGG and negative-sense RNA-specific 32 P-labelled primer, CGCAAGGCGACAAGGTGCTGA. Primer extensions were performed at 428C for 90 min. Transcription products were denatured at 908C for 10 min, separated on 6% polyacrylamide gels that contained 7 M urea in Tris/borate/EDTA (TBE) buffer and detected by autoradiography.
Quantitative real-time RT-PCR
Total RNA from transfected 293T cells was collected using an RNeasy Mini kit (Qiagen) following the manufacturer's instructions. The first-strand poly(A) cDNA was made using a SuperScript II reverse transcription kit (Invitrogen) following the manufacturer's instructions. The specific primers used for the green fluorescent protein (GFP) gene were as follows: sense, 5 0 -AGAACGGCATCAAGGTGAAC-3 0 ; and antisense, 5 0 -TGCTCAGGTAGTGGTTGTCG-3 0 . Values were normalized using the b-actin mRNA level. The primers for b-actin were as follows: sense, 5 0 -GCTCGTCGTCGACAACGGCTC-3 0 ; and antisense 5 0 -CAAACATGATCCTGGG TCATCTTCTC-3 0 . The PCR amplification yielded a product of 135 bp in length. The cDNA was amplified using SYBR green PCR mastermix (ABI), 5 mM of each primer and 0.5 mL of the cDNA product in a total volume of 20 mL. Forty cycles of PCR (one cycle consists of 10 min at 958C, 15 s at 958C and 1 min at 608C) were performed using ABI PRISM 7000 Sequence Detection systems. Melting curve analysis was performed to verify the specificity of the products; the relative values were calculated using the DDCt method. Each experiment was performed in triplicate.
CAT ELISA assay
293T cells were post-transfected for 48 h at 378C; the cell extract was then lysed by 500 mL of lysis buffer and tested for CAT levels using the CAT ELISA kit (Roche) following the manufacturer's instructions.
Selection of BPR2-D2-resistant and GS4071-resistant viruses
GS4071 is oseltamivir carboxylate and the active metabolite of oseltamivir. MDCK cells (4Â10 5 cells/well) were seeded in a 6-well plate and incubated for 24 h. The cells were washed in PBS and infected with A/WSN/33 at an MOI of 0.0005 pfu/cell. After 1 h of virus absorption the cells were washed twice and incubated in 2 mL of DMEM that contained 0.05 mM BPR2-D2 or 0.3 mM GS4071 (the EC 50 value of the compound) for 3 days. The EC 50 value of the compound was determined by counting the plaque number using the plaque reduction assay. The clear supernatant was collected and denoted passage 1. The passage 1 virus was used to infect a new cell monolayer (MOI of 0.0005 pfu/cell), which was further incubated in the presence of increasing concentrations of compound. The selection was performed using a total of 20 and 8 passages with BPR2-D2 and GS4071, respectively. Drug concentrations of BPR2-D2 were determined by doubling the concentrations from one passage to the next, from passage 1 to 11 (ranging from 0.05 to 51.2 mM), and then maintaining a constant concentration from passage 12 to 20 (51.2 mM). Drug concentrations of GS4071 ranged from 0.3 to 38.4 mM, doubling from one passage to the next over eight passages. Drug susceptibilities were determined by performing a neutralization test. GS4071 (oseltamivir carboxylate) was synthesized by Dr K.-S. Shia at the National Health Research Institutes (NHRI), Taiwan.
Haemagglutination (HA) assay
Serial 2-fold dilutions of virus samples were mixed with an equal volume of 0.5% chicken red blood cells (RBCs) in PBS and incubated on ice for 1 h in round-bottom 96-well plates. The titre was determined by noting the highest dilution of the virus that caused an HA reaction. Wells containing an adherent, homogeneous layer of erythrocytes were labelled as positive. A plaque assay was performed to estimate the reduced viral titre (pfu/mL) corresponding to the inhibition of HA. A series of 10-fold dilutions of samples was added to a monolayer of MDCK cells for 1 h at 378C. Overlay medium (3 mL) was then supplemented with 1% agarose, and the compound was added. Following incubation for 48 h at 378C, the cells were fixed with 10% formalin for 1 h. Following removal of the formalin, the cells were stained with Crystal Violet and plaques were visualized. Visible plaques were counted and then the concentration of pfu/mL was determined. The number of plaques was obtained from at least three independent experiments.
Results
Antiviral activity of BPR2-D2 Figure 1 displays the chemical structure of BPR2-D2, 8-benzoyl-4-methyl-9-phenyl-furo[2,3-h]chromen-2-one. BPR2-D2 was obtained from the hit identified from screening 20000 compounds by neutralization assay. A strain that is widely used in laboratories, influenza A/WSN/33 at an MOI of 0.001, was employed to infect MDCK cells and induce a CPE. Compounds that inhibited at least 50% of the CPE at a concentration of 1 mM were selected for further investigation of their antiviral activities. A plaque reduction assay was performed to verify the antiviral activity (Figure 2 ). An MOI 5Â10
24 of viruses was used to infect cells and a different concentration of compounds was present in the medium and the agarose throughout the viral adsorption (1 h) and 48 h post-infection. GS4071, an active form of oseltamivir, was used as a positive control in the plaque inhibition assay, and its EC 50 was 0.091+0.006 mM. BPR2-D2 was found to inhibit 100% of the virus-induced CPE at a concentration of 0.05 mM. The EC 50 of BPR2-D2 was 0.043+0.001 mM. There is no cytotoxicity observed by MTT assay with a concentration of BPR2-D2 of up to 25 mM. The cytotoxicity of BPR2-D2 was also examined by Crystal Violet staining of the attached live cells. Results of the analysis indicated that the CC 50 (i.e. the concentration of the compound that causes 50% cytotoxicity) exceeded 25 mM. The selective index (CC 50 /EC 50 ) is therefore .581 (25/0.043).
Inhibition of oseltamivir-resistant viruses
The antiviral efficacy of BPR2-D2 was then tested against oseltamivir-resistant viruses. The recent seasonal influenza A H1N1 viruses were found to be resistant to oseltamivir. 18, 25, 26 Accordingly, several clinical isolates of the H1N1 subtypes were tested to determine their susceptibilities to GS4071. (Table 1) .
Time-of-addition experiments in influenza A virus-infected cells
To elucidate further the antiviral mechanism of BPR2-D2, a time-of-addition assay was conducted in influenza A/WSN/ 33-infected MDCK cells. Figure 3(a) plots the time of the addition of BPR2-D2 during the course of the viral infection. BPR2-D2 inhibited 98% -100% of the production of the progeny virus when it was added before 4 h post-infection (Figure 3b) . A significant drop in the antiviral activity of the compound to 82% efficacy was observed when the compound was added 4 h post-infection, and the efficacy dropped further to 55% at 6 h and to 38% at 8 h post-infection. The results of the time-of-addition experiment in influenza A virus-infected cells suggest the potential involvement of BPR2-D2 in the early hours of viral replication.
Effects of BPR2-D2 on viral RNA synthesis that is driven by influenza A viral ribonucleoprotein (RNP) complex in transfected cells
Expression plasmids for PB2, PB1, PA and NP were transfected together with a plasmid that allowed expression of a pseudoviral reporter RNA (pPolI-CAT-RT plasmid) into 293 cells. 31 The levels of CAT protein were measured by ELISA. The results in Figure 4 (a) demonstrate that BPR2-D2 reduced the levels of CAT protein in a dosage-dependent manner, but had no significant effect when 25 mM (GS4071) or the solvent DMSO (0.25%) was present in the cell medium. The inhibition effect was unlikely to have been caused by an effect of the transfection efficiency because NP expression levels in all reactions were almost the same. To measure the levels of the transcription/replication of viral RNA, primer extension assays were performed using isotope-labelled primers that can differentiate among pseudoviral vRNA, cRNA and mRNA. The synthesis of viral mRNA and cRNA was strongly inhibited by BPR2-D2 but not by GS4071 or DMSO (Figure 4b ). This study also attempted to determine whether BPR2-D2 affects any other expressed mRNA; a polymerase II-driven gene (GFP) was also co-transfected with influenza viral RNP genes into cells. In Figure 4 (c), it can be seen that BPR2-D2 reduced the levels of CAT mRNA that was driven by viral RNP more significantly than those of GFP mRNA that was driven by cellular polymerase II. These results suggest that BPR2-D2 may target the viral RNP-associated function because it reduces the reporter gene expression when cells are transfected with viral RNP genes.
The effects of BPR2-D2 on viral RNA synthesis in influenza A virus-infected cells were also evaluated. MDCK cells were infected with A/WSN/33 at different viral titres (0.1-1 MOI) and treated or not with 0.025 mM BPR2-D2 (Figure 4d) . At 8 h post-infection, RNAs were extracted from infected cells and a primer extension assay was conducted. BPR2-D2 was found to inhibit viral RNA synthesis (lanes 7, 10 and 13), whereas the control solvent (DMSO) did not (lanes 6, 9 and 12). Taken together, the results in Figure 4 suggest that BPR2-D2 reduced viral RNA levels, possibly by interfering with the influenza viral RNP function.
Selection of BPR2-D2-resistant viruses
Monitoring the generation of resistant viruses was performed in cell cultures. The amount of BPR2-D2 increased in each successive passage of the virus-infected cells. The susceptibility to BPR2-D2 in every passage was evaluated by performing a neutralization test. The EC 50 from passage 1 to 20 ranged from 0.019 to 0.46 mM, indicating that all of the progeny viruses were susceptible to BPR2-D2 (Table 2) . However, the viruses that were resistant to GS4071 were produced in passage 8 when the culture medium contained GS4071. The results suggest that BPR2-D2-resistant viruses emerge less easily than do GS4071-resistant viruses.
Antiviral spectrum of BPR2-D2
The antiviral spectrum of BPR2-D2 was examined. Besides its activity against A/WSN/33, BPR2-D2 also exhibits antiviral activity against other strains of influenza A viruses and influenza B Shih et al.
viruses. Several clinical isolates that are resistant to another antiviral, amantadine, are susceptible to BPR2-D2 (Table 3) . Interestingly, BPR2-D2 also inhibited other RNA viruses, such as enterovirus 71, coxsackievirus B3 and HRV-2. No antiviral effect was found against HSV-2, a DNA virus.
The drug susceptibility of influenza A H5N1 to BPR2-D2 was also evaluated. Various concentrations of BPR2-D2 were added to the culture medium in which MDCK cells were infected by H5N1 viruses. Viral yields were measured by an HA test. The results in Figure 5 demonstrate that BPR2-D2 reduced the viral yield by .70% at a concentration of 0.02 mM and by almost 100% at 0.1 mM.
Discussion
Although two classes of antivirals are used in the clinical treatment of influenza viral infection, several works have demonstrated the emergence of viruses that are resistant to M2 ion channel inhibitors (amantadine and rimantadine) or NA inhibitors (oseltamivir and zanamivir). 15,17,19 -22,25,26 Accordingly, the urgency and significance of the development of novel antiviral agents that can inhibit such drug-resistant viruses are obvious. This study identified a compound, BPR2-D2, that inhibited oseltamivir-resistant influenza A viruses. Its chemical structure (Figure 1 ) appears to differ markedly from that of oseltamivir. The inhibition by BPR2-D2 of the oseltamivir-resistant virus is understood by considering the difference between its antiviral mechanism and that of oseltamivir. BPR2-D2 inhibited reporter gene expression that was driven by influenza viral RNPs. This compound reduced viral-like cRNA and mRNA levels in cells that had been co-transfected with a set of expression vectors that encoded PB1, PB2, PA, NP and a pseudoviral reporter RNA. The possibility that BPR2-D2 targets viral RNP-associated function is further supported by the observation herein that viral RNA levels declined in virus-infected cells when BPR2-D2 was added. The vRNA level in infected cells also decreased upon the addition of BPR2-D2, but was unaffected in transfected cells. This discrepancy may be caused by the following. First, vRNA was overexpressed by cellular polymerase I through the polI promoter in the plasmid. BPR2-D2 seemed not to inhibit cellular polymerase I activity. Secondly, the viral RNP protein expression levels in infected cells fell because the viral mRNA levels were affected by BPR2-D2. In transfected cells, viral RNPs were overexpressed from cellular polymerase II-driven plasmids and were not affected by BPR2-D2.
BPR2-D2 targets the viral RNP-associated function, and viral RNP has been found to be highly conserved among various strains of influenza virus. Hence, this compound is expected to BPR2-D2 inhibits oseltamivir-resistant influenza viruses 67 JAC exhibit a wide spectrum of antiviral activity. BPR2-D2 was demonstrated to inhibit various strains of influenza viruses effectively, including types A and B influenza viruses. Interestingly, BPR2-D2 also exhibited good antiviral activity against enterovirus 71, coxsackievirus B3 and HRV-2, which are three picornaviruses (Table 3) . BPR2-D2 displayed the ability to inhibit growth of both influenza viruses and picornaviruses, which exhibit various molecular mechanisms of viral RNA synthesis. Replication of picornaviral RNA that occurs via the RNA replication complex is associated with the membrane of virus-induced vesicles in the cytoplasm of infected cells. 32 A virus-encoded RNA polymerase 3D is the major component of the RNA replication complex, which contains other viral and host proteins. 33 -36 The purified 3D protein from the infected lysate exhibits the polymerase activity. 37 For viral RNA synthesis of negative-strand influenza virus, RNA polymerases are composed of three subunits, PB1, PB2 and PA. The RNA polymerases (PB1, PB2 and PA) and NP form a viral RNP with genomic RNA. Although polymerase components of picornaviruses and influenza viruses differ significantly from each other, the picornavirus 3D and influenza virus PB1 subunit share typical common motifs, as has been shown by specific sequence alignment.
38 BPR2-D2 may inhibit the virus by interacting with the conserved structures in these two viral polymerases. No crystal structures of the full-length PB1 have yet been obtained, although some studies have demonstrated that a portion of the crystal structure of the PB1 region interacting with PB2 or PA was Shih et al.
resolved. 39, 40 According to the results of amino acid sequence alignments, there are four conserved motifs (motifs A, B, C and D) among RNA-dependent RNA polymerases (RdRps). 38 All motifs are located in the palm domain, based on the crystal structures of poliovirus, encephalomyocarditis virus and hepatitis C virus polymerases. 41 Motif A is involved in magnesium coordination and possibly NTP selection. Although its function is unknown, motif B forms an a-helix that may be responsible for positioning the other motifs correctly. Motif C contains the highly conserved GDD motif found in RdRps. This GDD motif for poliovirus (SDD for influenza virus) is involved in magnesium coordination. Notably, motif D is the core palm structure.
Another possibility for its broad antiviral spectrum is that BPR2-D2 may target cellular proteins, which are involved in replicating both picornavirus and influenza viruses. A previous study identified heat shock protein 90 (Hsp90) as interacting with influenza virus PB2 protein and of being capable of stimulating vRNA synthesis. 42, 43 However, inhibition of Hsp90 functions by geldanamycin, a specific Hsp90 inhibitor, reduced poliovirus and coxsackievirus B and the replication ability of rhinoviruses.
44
BPR2-D2 may target such cellular proteins, which have an inhibitory effect on the replication of both viruses. However, the antiviral mechanism of BPR2-D2 against these viruses must be further clarified.
In the present study, the exact molecular target of BPR2-D2 is unclear. An attempt was made to identify the genetic markers that are associated with the drug-targeted molecule by selecting resistant viruses. However, we failed to select a BPR2-D2-resistant virus after 20 passages. An oseltamivirresistant virus appeared at passage 8 in the same culture system. Others have also reported the generation of oseltamivir resistance at early passages. 45 Although the failure of selection of resistant viruses impeded the investigation of the mechanism, it is a positive factor for BPR2-D2 as an antiviral agent because of the low probability of emergence of resistant viruses. The following may explain the difficulty in generation of BPR2-D2-resistant viruses. First, BPR2-D2 may target the highly conserved region of viral RNPs that is functionally essential for virus survival, such that its mutation is lethal or detrimentally affects the growth of the virus. Secondly, BPR2-D2 may target a cellular component that is functionally linked to BPR2-D2 inhibits oseltamivir-resistant influenza viruses several regions of viral RNPs such that a single or a few mutations in RNPs do not render this virus resistant. Moreover, BPR2-D2 inhibited RNA viruses other than orthomyxoviruses, which may hint that BPR2-D2 targets a viral/cellular factor that is common in these RNA viruses. In summary, a novel compound, BPR2-D2 was identified as a potent inhibitor against influenza virus using in vitro assay. It exhibited a broad range of antiviral activity against various strains of influenza viruses, including the H5N1 influenza A virus. This compound may target viral RNPs that are responsible for viral RNA synthesis. Targeting molecules other than NA and M2 allows BPR2-D2 to inhibit oseltamivir-and amantadine-resistant viruses efficiently.
